Inventor · disambiguated record
Francis Y. Lee
Also filed as: LEE FRANCIS Y · LEE FRANCIS Y F
27 granted patents·19 pending applications·607 citations·filing 2001–2023
96Inventor score
Top patents by PatentIndex Score
46 records- 0198US8119129B2Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseasesJURE-KUNKEL MARIA·Filed 2009·Granted Feb 21, 2012·165 cites·11 claims
- 0297US9458156B2Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Oct 4, 2016·25 cites·3 claims
- 0395US6537988B2Synergistic methods and compositions for treating cancerBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Mar 25, 2003·139 cites·53 claims
- 0494US7125875B2Cyclic protein tyrosine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Oct 24, 2006·74 cites·27 claims
- 0594US6686380B2Treatment of refractory tumors using epothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Feb 3, 2004·53 cites·15 claims
- 0692US9273014B2Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Mar 1, 2016·14 cites·11 claims
- 0791US7622472B2Combination of Src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Nov 24, 2009·9 cites·7 claims
- 0890US8629136B2Bisfluoroalkyl-1,4-benzodiazepinone compoundsGAVAI ASHVINIKUMAR V·Filed 2012·Granted Jan 14, 2014·25 cites·19 claims
- 0988US11744897B2Folate receptor targeted nanoparticle drug conjugates and uses thereofELUCIDA ONCOLOGY INC·Filed 2022·Granted Sep 5, 2023·2 cites·30 claims
- 1088US6727276B2Epothilone derivatives for the treatment of refractory tumorsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Apr 27, 2004·36 cites·20 claims
- 1186US8999918B2Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereofBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Apr 7, 2015·9 cites·19 claims
- 1285US7537891B2Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cellsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted May 26, 2009·8 cites·1 claims
- 1385US6936628B2Oral administration of epothilonesBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Aug 30, 2005·25 cites·64 claims
- 1482US8247419B2Methods of identifying and treating individuals exhibiting mutant kit proteinLEE FRANCIS Y·Filed 2006·Granted Aug 21, 2012·8 cites·12 claims
- 1581USRE41393ETreatment of refractory tumors using epothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jun 22, 2010·1 cites·28 claims
- 1674US11957760B2Folate receptor targeted nanoparticle drug conjugates and uses thereofELUCIDA ONCOLOGY INC·Filed 2023·Granted Apr 16, 2024·0 cites·30 claims
- 1774US9751879B2Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 5, 2017·1 cites·13 claims
- 1873US6773702B2Use of combretastatin A4 and its prodrugs as an immune enhancing therapyOXIGENE INC·Filed 2001·Granted Aug 10, 2004·5 cites·13 claims
- 1970US7504211B2Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cellsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Mar 17, 2009·3 cites·1 claims
- 2070US2023241243A1Carrier particle-drug conjugates, self-immolative linkers, and uses thereofELUCIDA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 2169US7799788B2Method of treating chronic myelogenous leukemia cellsUNIV SOUTH FLORIDA·Filed 2009·Granted Sep 21, 2010·0 cites·20 claims
- 2268US2009093495A1Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2008·Application pending·0 cites
- 2367US2009258937A1Methods for Modulating Tumor Growth and MetastasisLEE FRANCIS Y·Filed 2008·Application pending·0 cites
- 2467US2013142805A1Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 2565US8598215B2Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseasesLEE FRANCIS Y F·Filed 2009·Granted Dec 3, 2013·0 cites·5 claims
- 2664US10112941B2Tricyclic compounds as anticancer agentsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 30, 2018·0 cites·3 claims
- 2763US8673949B2Use of epothilone D in treating Tau-associated diseases including Alzheimer's diseaseALBRIGHT CHARLES F·Filed 2011·Granted Mar 18, 2014·2 cites·8 claims
- 2862US9492469B2Combination therapy for the treatment of proliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Nov 15, 2016·0 cites·11 claims
- 2960US7265260B2Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptorsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Sep 4, 2007·2 cites·11 claims
- 3060US2006046249A1Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathwaysHUANG FEI·Filed 2003·Application pending·0 cites
- 3160US2007166704A1Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathwaysHUANG FEI·Filed 2003·Application pending·0 cites
- 3258US7053069B2Pharmaceutical compositions and methods of using C-21 modified epothilone derivativesBRISTOL MYERS SQUIBB CO·Filed 2003·Granted May 30, 2006·1 cites·75 claims
- 3356US2009270465A1Use of epothilone d in treating tau-associated diseases including alzheimer's diseaseBRISTOL MYERS SQUIBB CO·Filed 2009·Application pending·0 cites
- 3455US8569347B2Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseasesLEE FRANCIS Y F·Filed 2004·Granted Oct 29, 2013·0 cites·10 claims
- 3555US2009054415A1Combinations, methods and compositions for treating cancerBRISTOL MYERS SQUIBB CO·Filed 2008·Application pending·0 cites
- 3655US2011033457A1Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2010·Application pending·0 cites
- 3751US2010029676A1T315a and f317i mutations of bcr-abl kinase domainSAWYERS CHARLES L·Filed 2006·Application pending·0 cites
- 3850US2006194770A1Methods for modulating tumor growth and metastasisLEE FRANCIS Y·Filed 2006·Application pending·0 cites
- 3946US2009306094A1Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase PolypeptidesBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
- 4045US2011112155A1Methods for treating cancer in patients having breast cancer resistance protein overexpressionBRISTOL MYERS SQUIBB CO·Filed 2009·Application pending·0 cites
- 4145US2009163510A1Methods of Identifying and Treating Individuals Exhibiting Mutant SRC Kinase PolypeptidesBRISTOL MYERS SQUIBB CO·Filed 2006·Application pending·0 cites
- 4244US2009099197A1Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations ThereofBRISTOL MYERS SQUIBB CO·Filed 2006·Application pending·0 cites
- 4344US2009197893A1Methods of Identifying and Treating Individuals Exhibiting Complex KaryotypesBRISTOL MYERS SQUIBB CO·Filed 2006·Application pending·0 cites
- 4442US2017326249A1Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and usesBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 4539US2007093499A1Use of dasatinib for the treatment of bone metastasisBRISTOL MYERS SQUIBB CO·Filed 2006·Application pending·0 cites
- 4635US2006069101A1Prodrugs of protein tyrosine kinase inhibitorsKIM KYOUNG S·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Francis Y. Lee files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →